Irbesartan and Adhesion Molecules in AF

PHASE4UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Persistent Atrial Fibrillation
Interventions
DRUG

irbesartan

Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.

DRUG

placebo

Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.

Trial Locations (1)

39120

RECRUITING

University Hospital Magdeburg; Div. of Cardiology, Magdeburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University of Magdeburg

OTHER

NCT00613496 - Irbesartan and Adhesion Molecules in AF | Biotech Hunter | Biotech Hunter